{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:23:06Z","timestamp":1780694586305,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"Abstract<\/jats:title>Importance<\/jats:title>Buprenorphine is a Schedule III analgesic that is recommended as the firstline long-acting opioid for the treatment of chronic pain due to its ceiling effect on respiratory depression, adverse effect profile, and analgesic efficacy. However, prescription drug coverage policies commonly require that patients try and fail multiple Schedule II conventional opioids before approval of on-label use of buprenorphine for chronic pain.<\/jats:p><\/jats:sec>Design<\/jats:title>A retrospective review was performed looking at coverage of buprenorphine in the forms of Butrans and Belbuca. Patient denial letters, web searches of insurance and pharmacy benefit managers (PBMs), and an online tool (formularylookup.com) were used to assess the coverage and availability of buprenorphine for chronic pain.<\/jats:p><\/jats:sec>Results<\/jats:title>Unrestricted access to Butrans was reported for 42% of commercial lives and 11% of Medicare lives in all locations. Unrestricted access to Belbuca was reported for 53% of commercial lives and 23% of Medicare lives in all locations. Oxycodone immediate-release has unrestricted access for 84% of commercial plans and 97% of Medicare plans. Morphine extended-release has unrestricted access for 62% of commercial lives and 65% of Medicare lives.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>There are &gt;17,000 prescription opioid\u2013involved deaths each year in the United States. By substituting buprenorphine as the firstline treatment for chronic and even acute pain, there may be fewer prescribed conventional opioids in the United States. Schedule III buprenorphine formulations for chronic pain should be given unrestricted access for appropriate patients before considering a Schedule II opioid as a public health priority.<\/jats:p><\/jats:sec>","DOI":"10.1093\/pm\/pnz197","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T19:11:46Z","timestamp":1562785906000},"page":"1005-1009","source":"Crossref","is-referenced-by-count":9,"title":["Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids"],"prefix":"10.1093","volume":"21","author":[{"given":"Michael A","family":"Fishman","sequence":"first","affiliation":[{"name":"Center for Interventional Pain and Spine, Exton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Scherer","sequence":"first","affiliation":[{"name":"Center for Interventional Pain and Spine, Exton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Topfer","sequence":"first","affiliation":[{"name":"Nova Southeastern University College of Osteopathic Medicine, Davie, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S H","family":"Kim","sequence":"first","affiliation":[{"name":"Center for Interventional Pain and Spine, Exton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"issue":"5152","key":"2020050811580132600_pnz197-B1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2020050811580132600_pnz197-B2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"key":"2020050811580132600_pnz197-B3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1191\/0269216306pm1126oa","article-title":"Opioid-induced respiratory effects: New data on buprenorphine","volume":"20(Suppl 1)","author":"Dahan","year":"2006","journal-title":"Palliat Med"},{"issue":"6","key":"2020050811580132600_pnz197-B4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"issue":"Trial I","key":"2020050811580132600_pnz197-B5","first-page":"345","article-title":"Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low back pain: Results from two randomized controlled trials","volume":"541","author":"Yarlas","year":"2015","journal-title":"Pain Pract"},{"issue":"6","key":"2020050811580132600_pnz197-B6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jcpt.12196","article-title":"The clinical analgesic efficacy of buprenorphine","volume":"39","author":"Raffa","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"2020050811580132600_pnz197-B7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1526-4637.2012.01408.x","article-title":"An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain","volume":"13","author":"Corli","year":"2012","journal-title":"Pain Med"},{"issue":"9","key":"2020050811580132600_pnz197-B8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2337\/dc16-0123","article-title":"Transdermal buprenorphine relieves neuropathic pain: A randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain","volume":"39","author":"Simpson","year":"2016","journal-title":"Diabetes Care"},{"key":"2020050811580132600_pnz197-B9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JPR.S120170","article-title":"Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids","volume":"10","author":"Hale","year":"2017","journal-title":"J Pain Res"},{"issue":"12","key":"2020050811580132600_pnz197-B10","doi-asserted-by":"crossref","first-page":"83.","DOI":"10.1007\/s11916-018-0732-2","article-title":"Buprenorphine for chronic pain: A systemic review","volume":"22","author":"Fishman","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"2020050811580132600_pnz197-B11"},{"issue":"6","key":"2020050811580132600_pnz197-B12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/bja\/aen094","article-title":"Opioids and the control of respiration","volume":"100","author":"Pattinson","year":"2008","journal-title":"Br J Anaesth"},{"issue":"3","key":"2020050811580132600_pnz197-B13","doi-asserted-by":"crossref","first-page":"137.","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"2020050811580132600_pnz197-B14","author":"Indivior","year":"2018"},{"issue":"1","key":"2020050811580132600_pnz197-B15","first-page":"1","article-title":"CDC guideline for prescribing opioids for chronic pain-United States, 2016. [Erratum appears in MMWR Recomm Rep 2016;65(11):295]","volume":"65","author":"Dowell","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"issue":"24","key":"2020050811580132600_pnz197-B16","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"key":"2020050811580132600_pnz197-B17","author":"Sullum"},{"key":"2020050811580132600_pnz197-B18"},{"issue":"4","key":"2020050811580132600_pnz197-B19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","article-title":"Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone)","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"key":"2020050811580132600_pnz197-B20","year":"2019"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/5\/1005\/33194041\/pnz197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/5\/1005\/33194041\/pnz197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T15:48:30Z","timestamp":1663948110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/21\/5\/1005\/5614401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,11,7]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnz197","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,11,7]]}}}